Compare INFQ & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFQ | AGIO |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2026 | 2013 |
| Metric | INFQ | AGIO |
|---|---|---|
| Price | $10.57 | $35.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | ★ 2.5M | 830.5K |
| Earning Date | N/A | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $74.95 |
| Revenue Next Year | N/A | $165.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.52 | $22.24 |
| 52 Week High | $13.70 | $46.00 |
| Indicator | INFQ | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 78.70 |
| Support Level | $10.32 | $32.68 |
| Resistance Level | $12.16 | $43.72 |
| Average True Range (ATR) | 0.94 | 1.34 |
| MACD | 0.05 | 0.73 |
| Stochastic Oscillator | 63.07 | 87.15 |
Infleqtion Inc develops and commercializes neutral atom-based quantum technology products through an integrated platform. Its offerings include quantum sensing, quantum computing, and related software solutions. The company's technologies are deployed across sectors such as defense and security, artificial intelligence, energy optimization, space applications, materials research, and cybersecurity. Its platform integrates core quantum technologies with hardware and proprietary software based on neutral atom systems.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.